-
Chinese Biopharma Bio-Bank Corp. Aims for HKEX IPO, Focused on PDGF Therapies
•
On November 22, 2024, B&K Corporation Limited (Bio-Bank Corp.), a biopharmaceutical company headquartered in China, has resubmitted its application for listing on the Hong Kong Stock Exchange (HKEX). The company is advised by joint sponsors Hua Tai International and CITIC Securities. Company Background and Therapeutic FocusFounded in 2012, Bio-Bank Corp.…
-
Protein Drug Developer B&K Co., Ltd from Qingdao Eyes Hong Kong IPO
•
B&K Co., Ltd, known as Bio-Bank Corp., a biopharmaceutical company specializing in protein drug development and headquartered in Qingdao, has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange. The company’s IPO details, including pricing, have not yet been disclosed. Since its establishment in 2012, B&K…
-
Bio-Bank Corp. Aims for HKEX IPO with Focus on PDGF Drug Development
•
B&K Corporation Limited, known as Bio-Bank Corp., has recently filed an initial public offering (IPO) prospectus with the Hong Kong Stock Exchange (HKEX), intending to list on the main board. The joint sponsors for the listing are Hua Tai International and CITIC Securities. Company Background and Therapeutic FocusEstablished in 2012,…
